制度创新 服务外资企业增资扩产

Group 1 - The core viewpoint of the articles emphasizes the importance of institutional innovation and the expansion of foreign investment in Tianjin, particularly highlighting the significant investment by Novo Nordisk in the biopharmaceutical sector [1][2] - Novo Nordisk has invested nearly 5 billion yuan in Tianjin over the past two years, with a focus on expanding its sterile formulation project, which is nearing completion [1][2] - The company has established a strong presence in China, having introduced 22 innovative drugs and 11 injection devices, with 70% of its 400+ suppliers located in the Beijing-Tianjin-Hebei region [1] Group 2 - The establishment of a service team by the Tianjin municipal government, in collaboration with various departments, has facilitated Novo Nordisk's acquisition of the segmented production qualification for biopharmaceuticals [2] - In July, Novo Nordisk invested approximately 800 million yuan to expand its quality testing laboratory in Tianjin, reflecting the company's growing confidence in the local market [2] - The local government aims to further support foreign enterprises in integrating into the domestic market and enhancing their production capabilities through institutional innovation [2]